Gerald McLaughlin

NuPathe, Inc. develops pharmaceutical and therapeutic products. It focuses on the development and commercialization of branded therapeutics for diseases of central nervous system, including neurological and psychiatric disorders. The company was founded by Terri B. Sebree and Jane Holmes Hollingsworth in 2005 and is headquartered in Malvern, PA.

Endo Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products. The company provides research and development of generic pharmaceutical products for controlling pain. Its product includes Lidoderm, Percocet, Percodan, Frova, DepoDur, and Zydone. The company is headquartered in Malvern, PA.

AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD.

Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.

Life Biosciences, Inc. engages in the provision of research on aging and age-related diseases. It focuses on altered communication and inflammation, chromosomal instability, cellular senescence, loss of protoeostasis, metabolism, stem cell exhaustion, epigenetic alterations, and mitochondrial dysfunction. The company was founded by David Sinclair and Tristan Alexander Edwards in 2017 and is headquartered in Boston, MA.